Pruritus - Pipeline Review, H1 2018

Publisher Name :
Date: 27-Feb-2018
No. of pages: 134
Inquire Before Buying

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Pipeline Review, H1 2018, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 15, 3, 1 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note : Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).

  • The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Pruritus - Pipeline Review, H1 2018

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Pruritus - Overview
Pruritus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Pruritus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pruritus - Companies Involved in Therapeutics Development
Albireo Pharma Inc
Allergan Plc
Amgen Inc
Amorepacific Corp
Asana BioSciences LLC
Cara Therapeutics Inc
Celgene Corp
Chugai Pharmaceutical Co Ltd
ELORAC Inc
GlaxoSmithKline Plc
Hydra Biosciences Inc
Japan Tobacco Inc
NeuroCycle Therapeutics GmbH
Patagonia Pharmaceuticals LLC
Patara Pharma Inc
RDD Pharma Ltd
Sanwa Kagaku Kenkyusho Co Ltd
Sienna Biopharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Teikoku Pharma USA Inc
Tesaro Inc
Tioga Pharmaceuticals Inc
Toray Industries Inc
Vanda Pharmaceuticals Inc
Pruritus - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-8379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apremilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASN-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bepotastine besilate SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
difelikefalin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JTS-661 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalbuphine hydrochloride ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalfurafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naloxone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCT-10004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nemolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPK-88002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orvepitant maleate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PATN-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
phenylbutyrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PR-38 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-1609 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
serlopitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SK-1405 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize KOR1 for Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TRPV3 for Pain,Pruritus and Psoriasis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SNA-125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPU-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tradipitant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VVZ-149 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pruritus - Dormant Projects
Pruritus - Discontinued Products
Pruritus - Product Development Milestones
Featured News & Press Releases
Feb 14, 2018: Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
Jan 31, 2018: Cara Therapeutics Initiates Pivotal Phase 3 Efficacy Trial of KORSUVA (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
Nov 21, 2017: Menlo Therapeutics Begins Phase 2 Clinical Trial for Pruritus Associated with Psoriasis
Oct 31, 2017: Cara Therapeutics to Present Late-Breaking Data at the American College of Rheumatology ACR/ARHP Annual Meeting
Oct 24, 2017: Sienna Biopharmaceuticals Announces First Patient Dosed in Phase 2b Trial of Topical SNA-120
Oct 17, 2017: Cara Therapeutics Announces Participation in ANESTHESIOLOGY 2017
Oct 17, 2017: Menlo Therapeutics Expands its Management Team
Oct 16, 2017: Cara Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA for I.V. CR845 in Chronic Kidney Disease-Associated Pruritus
Oct 16, 2017: Cara Therapeutics to Present Data at Kidney Week 2017
Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017
Sep 22, 2017: Toray Receives Japanese Approval for an Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5µg and REMITCH OD Tablets 2.5µg
Sep 18, 2017: Serlopitant Pruritus Reduction Results from Two Phase 2 Studies Presented at the 26th European Academy of Dermatology and Venereology
Sep 13, 2017: Vanda's Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis
Aug 01, 2017: Cara Therapeutics Appoints Mani Mohindru, Ph.D., Chief Financial Officer
Jun 23, 2017: Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Pruritus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pruritus - Pipeline by Albireo Pharma Inc, H1 2018
Pruritus - Pipeline by Allergan Plc, H1 2018
Pruritus - Pipeline by Amgen Inc, H1 2018
Pruritus - Pipeline by Amorepacific Corp, H1 2018
Pruritus - Pipeline by Asana BioSciences LLC, H1 2018
Pruritus - Pipeline by Cara Therapeutics Inc, H1 2018
Pruritus - Pipeline by Celgene Corp, H1 2018
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Pruritus - Pipeline by ELORAC Inc, H1 2018
Pruritus - Pipeline by GlaxoSmithKline Plc, H1 2018
Pruritus - Pipeline by Hydra Biosciences Inc, H1 2018
Pruritus - Pipeline by Japan Tobacco Inc, H1 2018
Pruritus - Pipeline by NeuroCycle Therapeutics GmbH, H1 2018
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, H1 2018
Pruritus - Pipeline by Patara Pharma Inc, H1 2018
Pruritus - Pipeline by RDD Pharma Ltd, H1 2018
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2018
Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, H1 2018
Pruritus - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018
Pruritus - Pipeline by Teikoku Pharma USA Inc, H1 2018
Pruritus - Pipeline by Tesaro Inc, H1 2018
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, H1 2018
Pruritus - Pipeline by Toray Industries Inc, H1 2018
Pruritus - Pipeline by Vanda Pharmaceuticals Inc, H1 2018
Pruritus - Dormant Projects, H1 2018
Pruritus - Dormant Projects, H1 2018 (Contd..1), H1 2018
Pruritus - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Pruritus, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Hyaluronic Acid Dermal Filler Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 88
    Hyaluronic Acid Dermal Filler are The product can be used to smooth away wrinkles and fine line, create fuller and more accentuated lips, and adding facial volume and contour. The global Hyaluronic Acid Dermal Filler market was valued at US$ 2682.8 million in 2023 and is anticipated to reach US$ 5035.7 million by 2030, witnessing a CAGR of 9.3% during The forecast period 2024-2030. The producers mainly located in Europe, United States, China and Korea, such as Allergan,......
  • Global Hyaluronic Acid Based Dermal Fillers Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 134
    According to our LPI (LP Information) latest study, the global Hyaluronic Acid Based Dermal Fillers market size was valued at US$ 2195.2 million in 2023. With growing demand in downstream market, the Hyaluronic Acid Based Dermal Fillers is forecast to a readjusted size of US$ 3708.9 million by 2030 with a CAGR of 7.8% during review period. The research report highlights the growth potential of the global Hyaluronic Acid Based Dermal Fillers market. Hyaluronic Acid Based Dermal Fillers ar......
  • Global Dermal Fillers Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 112
    According to our LPI (LP Information) latest study, the global Dermal Fillers market size was valued at US$ 5342.2 million in 2023. With growing demand in downstream market, the Dermal Fillers is forecast to a readjusted size of US$ 15850 million by 2030 with a CAGR of 16.8% during review period. The research report highlights the growth potential of the global Dermal Fillers market. Dermal Fillers are expected to show stable growth in the future market. However, product differentiation,......
  • Global Hyaluronic Acid Dermal Filler Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Hyaluronic Acid Dermal Filler market size was valued at US$ 2624.4 million in 2023. With growing demand in downstream market, the Hyaluronic Acid Dermal Filler is forecast to a readjusted size of US$ 5000.7 million by 2030 with a CAGR of 9.6% during review period. The research report highlights the growth potential of the global Hyaluronic Acid Dermal Filler market. Hyaluronic Acid Dermal Filler are expected to show stable gr......
  • Global Pressure Ulcer Treatment Products Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 118
    According to our LPI (LP Information) latest study, the global Pressure Ulcer Treatment Products market size was valued at US$ 2150.3 million in 2023. With growing demand in downstream market, the Pressure Ulcer Treatment Products is forecast to a readjusted size of US$ 3021.5 million by 2030 with a CAGR of 5.0% during review period. The research report highlights the growth potential of the global Pressure Ulcer Treatment Products market. Pressure Ulcer Treatment Products are expected t......
  • Global Dermatology Drug Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 108
    According to our LPI (LP Information) latest study, the global Dermatology Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the Dermatology Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Dermatology Drug market. Dermatology Drug are expected to show stable growth in the future market. However, product differentiation, reducing ......
  • Global Pruritus Therapeutics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 109
    According to our LPI (LP Information) latest study, the global Pruritus Therapeutics market size was valued at US$ 13380 million in 2023. With growing demand in downstream market, the Pruritus Therapeutics is forecast to a readjusted size of US$ 17790 million by 2030 with a CAGR of 4.1% during review period. The research report highlights the growth potential of the global Pruritus Therapeutics market. Pruritus Therapeutics are expected to show stable growth in the future market. However......
  • Global Scar Treatment Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 109
    According to our LPI (LP Information) latest study, the global Scar Treatment market size was valued at US$ 956.9 million in 2023. With growing demand in downstream market, the Scar Treatment is forecast to a readjusted size of US$ 1584.4 million by 2030 with a CAGR of 7.5% during review period. The research report highlights the growth potential of the global Scar Treatment market. Scar Treatment are expected to show stable growth in the future market. However, product differentiation, ......
  • Global Botox Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 92
    According to our LPI (LP Information) latest study, the global Botox market size was valued at US$ 4597.8 million in 2023. With growing demand in downstream market, the Botox is forecast to a readjusted size of US$ 9055 million by 2030 with a CAGR of 10.2% during review period. The research report highlights the growth potential of the global Botox market. Botox are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain opt......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs